Complivit Calcium D3 forte, chewable mint pills, 100pcs

Composition

Calcium 500 mg, (in the form of calcium carbonate) 1,25 g

Colecalciferol (VitaminD3) 0.01 mg (400 IU)

(in terms of 100% colecalciferol)

(in the form of granules containing colecalciferol and 0.27%, respectively, of D, L-alpha-tocopherol – 0,0275%, triglycerides medium-chain – 10,7%, sucrose – 36%, gum acacia – 22%, corn starch – 27%, calcium phosphate (E 341), and 0.5%, water up to 100%).

Excipients: lactose monohydrate – 333,118 mg/333,118 mg, povidone (polyvinylpyrrolidone middle, povidone K-30) – of 68.24 mg/of 68.24 mg, Polysorbate-80 – 0 mg/1,731 mg, potato starch – 18,969 mg/18,969 mg, croscarmellose sodium – 45,713 mg/50,282 mg, citric acid monohydrate – 3,325 mg/3,325 mg, aspartame (E 951) – 5,95 mg/5,95 mg, magnesium stearate – is 15.75 mg/15,75 mg orange flavor – 8,925 mg or peppermint leaf oil 2,625 mg.

Pharmacological properties

Pharmacotherapeutic group: calcium-phosphorus metabolism regulator.

ATX code: [A 12 AH].

Pharmacological properties

Pharmacodynamics

A combined drug, the action of which is due to the components included in its composition. Regulates the exchange of calcium and phosphates, reduces resorption and increases bone density, makes up for the lack of calcium and vitamin D3 in the body, increases the absorption of calcium in the intestines and reabsorption of phosphates in the kidneys, promotes bone mineralization.

Calcium-participates in the formation of bone tissue, blood clotting, maintaining stable heart activity, and carrying out the processes of transmitting nerve impulses.

Vitamin D3 (colecalciferol) – promotes the absorption of calcium in the intestines, the formation and mineralization of bone and tooth tissue.

The use of calcium and vitamin D3 prevents an increase in the production of parathyroid hormone, which is a stimulator of increased bone resorption.

Pharmacokinetics

Vitamin D3 is absorbed in the small intestine. Calcium is absorbed in ionized form in the proximal small intestine through an active, D-vitamin-dependent transport mechanism.

Indications

Prevention and complex therapy of osteoporosis (menopausal, senile, “steroid”, idiopathic) and its complications (bone fractures).

Replenishment of calcium and/or vitamin D3 deficiency.

Use during pregnancy and lactation

The daily dose should not exceed 1500 mg of calcium and 600 IU_{of vitamin}D3. Hypercalcemia, which develops on the background of an overdose, during pregnancy can cause defects in the child’s mental and physical development. Vitamin D and its metabolites can enter breast milk, so it is necessary to take into account the intake of calcium and vitamin D from other sources in the mother and child.

Contraindications

Hypersensitivity to the components of the drug (including lactose intolerance, lactase deficiency, glucose-galactose malabsorption), hypercalcemia, hypercalciuria, calcium nephrourolithiasis, hypervitaminosis D, decalcifying tumors (myeloma, bone metastases, sarcoidosis), osteoporosis due to immobilization, phenylketonuria (contains aspartame), pulmonary tuberculosis (active form), chronic renal failure, children under 3 years of age.

Use with caution: pregnancy, lactation.

Side effects

Dyspeptic disorders of the gastrointestinal tract (constipation, flatulence, nausea, stomach pain, diarrhea). Allergic reactions. Hypercalcemia and hypercalciuria (increased calcium content in the blood and urine).

Interaction

Vitamin D3 activity may be reduced when co-administered with phenytoin or barbiturates.

Simultaneous treatment with cardiac glycosides requires monitoring of the ECG and clinical condition, since calcium supplements can potentiate the therapeutic and toxic effects of cardiac glycosides.

Calcium and vitamin D3 supplements may increase the absorption of tetracyclines from the gastrointestinal tract. Therefore, the time interval between taking medications should be at least three hours.

To prevent a decrease in the absorption of bisphosphonate preparations or sodium fluoride, it is recommended to take Complivit ® Calcium D₃ Forte no earlier than two hours after taking them.

Glucocorticosteroids reduce the absorption of calcium, so treatment with glucocorticosteroids may require an increase in the dose of Complivit ® Calcium D₃ Forte.

Concomitant treatment with colestyramine or mineral or vegetable oil-based laxatives may reduce the absorption_{of vitamin}D3.

Concomitant use of thiazide-type diuretics increases the risk of hypercalcemia, as they increase the tubular reabsorption of calcium. Furosemide and other “loop” diuretics, on the contrary, increase the excretion of calcium by the kidneys.

How to take, course of use and dosage

Inside, chewed or swallowed whole, mainly during meals.

Adults: for the treatment of osteoporosis-1 tablet 2-3 times a day, for the prevention of osteoporosis-1 tablet 2 times a day.

To compensate for calcium and/or vitamin D3 deficiency:

• Adults and children over 12 years of age – 1 tablet 1-2 times a day.

• Children from 3 to 12 years – 1 tablet per day or as prescribed by a doctor.

Overdose

If you find signs of overdose, consult your doctor.

Symptoms: thirst, polyuria, decreased appetite, nausea, vomiting, constipation, dizziness, weakness, headache, fainting states, coma; with prolonged use: calcification of blood vessels and tissues.

Treatment: the introduction of a large amount of fluid into the body, the use of “loop” diuretics (for example, furosemide), glucocorticosteroids, calcitonin, bisphosphonates.

If clinical symptoms of overdose develop, the concentration of calcium and creatinine in the blood should be determined. If there is an increased concentration of calcium or creatinine in the blood serum, the dose of the drug should be reduced or treatment should be temporarily discontinued.

Special instructions

In order to avoid overdose, additional intake_{of vitamin} D3 from other sources should be considered.

Complivit ® Calcium D₃ Forte contains aspartame, which is converted to phenylalanine in the body, so the drug should not be taken by patients suffering from phenylketonuria.

During treatment, it is necessary to constantly monitor the excretion of calcium in the urine and the concentration of calcium and creatinine in the blood plasma (in case of calciuria exceeding 7.5 mmol/day (300 mg/day), it is necessary to reduce the dose or stop taking it).

In the elderly, the need for calcium is 1500 mg / day, in vitamin D₃ – 0,5-1 ths. IU/day.

Form of production

Chewable peppermint tablets.

Storage conditions

At a temperature not exceeding 25 °C. Keep out of reach of children.

Shelf

life is 3 years.

Active ingredient

: Calcium carbonate, Colecalciferol

Dosage form

tablets for resorption

Indications

Bone Strengthening